Akorn receives FDA approval for loteprednol etabonate ophthalmic suspension, 0.5%
LAKE FOREST, Ill. –Akorn announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for loteprednol etabonate ophthalmic suspension, 0.5%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.